These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 11157684)

  • 1. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment.
    Gieffers J; Füllgraf H; Jahn J; Klinger M; Dalhoff K; Katus HA; Solbach W; Maass M
    Circulation; 2001 Jan; 103(3):351-6. PubMed ID: 11157684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study.
    Anderson JL; Muhlestein JB; Carlquist J; Allen A; Trehan S; Nielson C; Hall S; Brady J; Egger M; Horne B; Lim T
    Circulation; 1999 Mar; 99(12):1540-7. PubMed ID: 10096928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation of Chlamydophila pneumoniae from atheromas of the carotid artery and their antibiotics susceptibility profile.
    Cuffini C; Alberto Guzmán L; Villegas N; Eduardo Alonso C; Martínez-Riera L; Rodríguez-Fermepín M; Carolina Entrocassi A; Pilar Adamo M; Pedranti M; Zapata M
    Enferm Infecc Microbiol Clin; 2006 Feb; 24(2):81-5. PubMed ID: 16545314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells.
    Gieffers J; Solbach W; Maass M
    Cardiovasc Drugs Ther; 2001; 15(3):259-62. PubMed ID: 11713894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.
    Dreses-Werringloer U; Padubrin I; Zeidler H; Köhler L
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3001-8. PubMed ID: 11600348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherogenetically relevant cells support continuous growth of Chlamydia pneumoniae.
    Maass M; Gieffers J; Solbach W
    Herz; 2000 Mar; 25(2):68-72. PubMed ID: 10829241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth cycle-dependent pharmacodynamics of antichlamydial drugs.
    Siewert K; Rupp J; Klinger M; Solbach W; Gieffers J
    Antimicrob Agents Chemother; 2005 May; 49(5):1852-6. PubMed ID: 15855506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of PEX, a noncatalytic metalloproteinase fragment with integrin-binding activity, on experimental Chlamydophila pneumoniae infection.
    Caronzolo D; Lucini V; Pannacci M; Grosso S; Kieffer N; Bello L; Bikfalvi A; Scaglione F
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3277-82. PubMed ID: 17005805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model.
    Kutlin A; Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 2002 Feb; 46(2):409-12. PubMed ID: 11796350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae.
    Riska PF; Kutlin A; Ajiboye P; Cua A; Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3586-90. PubMed ID: 15328134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model.
    Kutlin A; Roblin PM; Hammerschlag MR
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2268-72. PubMed ID: 10471577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model.
    Kutlin A; Roblin PM; Hammerschlag MR
    J Antimicrob Chemother; 2002 May; 49(5):763-7. PubMed ID: 12003969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sustained antibiotic bactericidal treatment on Chlamydia trachomatis-infected epithelial-like cells (HeLa) and monocyte-like cells (THP-1 and U-937).
    Mpiga P; Ravaoarinoro M
    Int J Antimicrob Agents; 2006 Apr; 27(4):316-24. PubMed ID: 16527461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease.
    Wong YK; Dawkins KD; Ward ME
    J Am Coll Cardiol; 1999 Nov; 34(5):1435-9. PubMed ID: 10551689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease.
    Gupta S
    Am Heart J; 1999 Nov; 138(5 Pt 2):S539-41. PubMed ID: 10539869
    [No Abstract]   [Full Text] [Related]  

  • 16. Chlamydia pneumoniae resists antibiotics in lymphocytes.
    Yamaguchi H; Friedman H; Yamamoto M; Yasuda K; Yamamoto Y
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1972-5. PubMed ID: 12760877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of levofloxacin on the viability of intracellular Chlamydia pneumoniae and modulation of proinflammatory cytokine production by human monocytes.
    Baltch AL; Smith RP; Ritz WJ; Carpenter AN; Bopp LH; Michelsen PB; Carlyn CJ; Hibbs JR
    Diagn Microbiol Infect Dis; 2004 Nov; 50(3):205-12. PubMed ID: 15541607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chlamydia pneumoniae in an ex vivo human artery culture model.
    Poppert S; Schlaupitz K; Marre R; Voisard R; Roessler W; Weckermann D; Weingärtner K; Essig A
    Atherosclerosis; 2006 Jul; 187(1):50-6. PubMed ID: 16202418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmission of Chlamydia pneumoniae infection from blood monocytes to vascular cells in a novel transendothelial migration model.
    Rupp J; Koch M; van Zandbergen G; Solbach W; Brandt E; Maass M
    FEMS Microbiol Lett; 2005 Jan; 242(2):203-8. PubMed ID: 15621438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of Chlamydia pneumoniae to azithromycin and doxycycline: methodological aspects on the determination of minimal inhibitory and minimal bactericidal concentrations.
    Nyström-Rosander C; Hultén K; Gustavsson I; Cars O; Engstrand L; Hjelm E
    Scand J Infect Dis; 1997; 29(5):513-6. PubMed ID: 9435043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.